Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?

• Published in: World journal of surgical oncology Vol. 10; no. 1; p. 111
• Main Authors: Tielen, Ronald, Verhoef, Cornelis, van Coevorden, Frits, Gelderblom, Hans, Sleijfer, Stefan, Hartgrink, Henk H, Bonenkamp, Johannes J, van der Graaf, Winette T, de Wilt, Johannes H W
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 15.06.2012; BioMed Central; BMC
• Subjects: Abdominal surgery; Adult; Aged; Aged, 80 and over; Analysis; Antimitotic agents; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Benzamides; Care and treatment; Combined Modality Therapy; Development and progression; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal stromal tumors; Gastrointestinal Stromal Tumors - drug therapy; Gastrointestinal Stromal Tumors - mortality; Gastrointestinal Stromal Tumors - secondary; Gastrointestinal Stromal Tumors - surgery; Gastrointestinal tumors; Humans; imatinib; Imatinib Mesylate; Indoles - administration & dosage; Male; Metastasis; Middle Aged; Neoplasm Recurrence, Local - diagnosis; Neoplasm Recurrence, Local - mortality; Neoplasm Staging; overall survival; Patient outcomes; Piperazines - administration & dosage; Prognosis; progression-free survival; Pyrimidines - administration & dosage; Pyrroles - administration & dosage; Retrospective Studies; sunitinib; Surgery; Survival Rate; Young Adult; Netherlands

Standard treatment for metastatic gastrointestinal stromal tumors (GISTs) is systemic therapy with imatinib. Surgery is performed to remove metastatic lesions to induce long-term remission or even curation. In other patients, surgery is performed to remove (focal) progressive or symptomatic lesions....